A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells.
TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) is a novel, synthetic retinoid that is effective against liver metastases of human gastrointestinal cancer cells such as the human stomach carcinoma line AZ-521 in animal models, and is currently in use in phase I cancer trials. However, the mechanism of its antimetastatic action is still poorly understood. Tumor metastasis depends on angiogenesis, and various retinoids have been found to exhibit antiangiogenic activity. Based on these findings we here examined the antiangiogenic effects of TAC-101. Oral administration of TAC-101 (2-8 mg/kg/day) resulted in a drastic suppression of the AZ-521 cell-induced angiogenesis in a mouse dorsal air sac assay system, compared to the vehicle alone. Immunohistochemical analysis with antibody against the endothelial marker CD31 revealed a significant reduction in microvessel density in liver metastases from animals treated with TAC-101 (8 mg/kg p.o.), compared to liver metastases from the untreated control animals. The ability of TAC-101 (8 mg/kg p.o.) to prevent experimental liver metastasis of AZ-521 cells in athymic nude mice was comparable with that of the known angiogenesis inhibitor TNP-470 (30 mg/kg s.c.). TAC-101 also affected angiogenesis in chorioallantoic membranes and some functions of endothelial cells associated with angiogenesis, whereas the retinoid failed to suppress AZ-521 cell proliferation directly. These data suggest that the TAC-101 is an orally active antiangiogenic agent and that this antiangiogenic property may contribute to its efficacy against liver metastasis of human stomach cancer cells.
Oikawa
T
T
Pharmaceutical Research and Development Center, The Tokyo Metropolitan Institute of Medical Science (Rinshoken), Tokyo Metropolitan Organization for Medical Research, Bunkyo-ku, Tokyo 113-8613. oikawa@rinshoken.or.jp
Murakami
K
K
Sano
M
M
Shibata
J
J
Wierzba
K
K
Yamada
Y
Y
D000284:Administration, Oral; D000818:Animals; D001565:Benzoates / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D003510:Cyclohexanes; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000556:secondary*; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D012717:Sesquiterpenes / Q000494:pharmacology; D013274:Stomach Neoplasms / Q000473:pathology*; D014297:Trimethylsilyl Compounds / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
D001565:Benzoates; D003510:Cyclohexanes; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D012717:Sesquiterpenes; C112689:TAC 101; D014297:Trimethylsilyl Compounds; D002945:Cisplatin; D000077609:O-(Chloroacetylcarbamoyl)fumagillol